- Home
- IPM vs CALC Comparison
IPM vs CALC Comparison
Compare IPM & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPM
- CALC
- Stock Information
- Founded
- IPM 2005
- CALC 2011
- Country
- IPM United States
- CALC United States
- Employees
- IPM N/A
- CALC 15
- Industry
- IPM
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- IPM
- CALC Health Care
- Exchange
- IPM NYSE
- CALC Nasdaq
- Market Cap
- IPM 27.9M
- CALC 22.9M
- IPO Year
- IPM N/A
- CALC N/A
- Fundamental
- Price
- IPM $1.92
- CALC $1.43
- Analyst Decision
- IPM Strong Buy
- CALC Strong Buy
- Analyst Count
- IPM 1
- CALC 3
- Target Price
- IPM $6.00
- CALC $16.33
- AVG Volume (30 Days)
- IPM 43.0K
- CALC 22.6K
- Earning Date
- IPM 08-13-2025
- CALC 08-11-2025
- Dividend Yield
- IPM N/A
- CALC N/A
- EPS Growth
- IPM N/A
- CALC N/A
- EPS
- IPM N/A
- CALC N/A
- Revenue
- IPM $6,344,746.00
- CALC N/A
- Revenue This Year
- IPM $1,957.49
- CALC N/A
- Revenue Next Year
- IPM $17.96
- CALC N/A
- P/E Ratio
- IPM N/A
- CALC N/A
- Revenue Growth
- IPM 14.16
- CALC N/A
- 52 Week Low
- IPM $1.52
- CALC $1.43
- 52 Week High
- IPM $5.50
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- IPM N/A
- CALC 32.78
- Support Level
- IPM N/A
- CALC $1.48
- Resistance Level
- IPM N/A
- CALC $1.79
- Average True Range (ATR)
- IPM 0.00
- CALC 0.12
- MACD
- IPM 0.00
- CALC -0.02
- Stochastic Oscillator
- IPM 0.00
- CALC 0.00
About IPM INTELLIGENT PROTECTION MANAGEMENT
Intelligent Protection Management Corp is a communications software innovator that powers multimedia social applications.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.